Press Releases Eli Lilly and Company

Equities

LLY

US5324571083

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 11:28:21 22/04/2026 pm IST			5-day change	1st Jan Change
918.30 ^USD	+1.69%		+1.47%	-14.55%

06:50pm	REPEAT & CORRECT : Amazon Launches Program for GLP-1 Weight-Loss Drugs Article on April 21	DJ
06:46pm	Delay in Medicare pilot for obesity drugs may not hurt near-term demand, analysts say	RE

Press Releases

20/04	Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies	PR
16/04	Lilly confirms date and conference call for first-quarter 2026 financial results announcement	PR
16/04	ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health	PR
15/04	CrossBridge Bio Enters an Agreement to be Acquired by Eli Lilly to Advance Next-Generation Dual-Payload Antibody-Drug Conjugates	AQ
13/04	LifeMD(R) Now Offering Eli Lilly and Company's Foundayo (orforglipron), a New GLP-1 Pill for Weight Management	AQ
13/04	Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL	PR
10/04	Amazon Pharmacy to Offer Eli Lilly and Company's New GLP-1 Pill Foundayo via Same-Day Delivery	AQ
10/04	GoodRx Expands Access to Eli Lilly and Company's New Oral GLP-1, Foundayo, and Zepbound KwikPen with Self-Pay Pricing at More Than 70,000 Pharmacies Nationwide	AQ
09/04	Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S.	PR
09/04	Eli Lilly and : 2026 Estimated Acquired IPR&D And Development Milestone Charges for Q1 2026	PU
01/04	FDA approves Eli Lilly's GLP-1 weight-loss pill	AQ
01/04	FDA grants speedy approval to Eli Lilly's weight-loss pill for obesity	AQ
01/04	FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions	PR
30/03	Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis	AQ
30/03	Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz plus Zepbound delivered superior efficacy for adults with psoriatic arthritis and obesity	AQ
30/03	TGFB Inhibitors Competitive Landscape & Pipeline 2026: Emerging Therapies, Leading Companies, and Future Outlook	AQ
29/03	Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity	PR
27/03	AAD 2026: Almirall Presents New Clinical and Real-world Evidence Across Atopic Dermatitis, Psoriasis, Actinic Keratosis and Acne	AQ
27/03	Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis	PR
22/03	Pharmaceutical firm Eli Lilly invests 3 billion dollars in China for slimming drug	AQ
19/03	Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes	PR
16/03	Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis	PR
13/03	Indiana Sues Eli Lilly Over Skyrocketing Insulin Prices	AQ
13/03	Media Statement: Zepbound (tirzepatide) KwikPen now available at self-pay pricing at major pharmacies nationwide in addition to LillyDirect	PU
12/03	Andel Launches New Direct-to-Employer Medication Platform to Make GLP-1s Affordable for Millions	AQ